FDA Drug recall D-1302-2022
Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 180 mg, 30-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, I…
- FDA Drug
- Class II
- terminated
- Published 2022-08-10
On 2022-08-10 the FDA classified a Class II recall of Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 180 mg, 30-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, I… by Teva Pharmaceuticals Usa, citing failed Dissolution Specifications: below specification limits for dissolution.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1302-2022 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2022-07-21 |
| Published | 2022-08-10 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Teva Pharmaceuticals Usa |
| Distribution | US |
Product
Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 180 mg, 30-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, USA; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA; NDC 52544-691-30.
Reason
Failed Dissolution Specifications: below specification limits for dissolution.
Identifiers
| ndc | 52544-691-30 |
|---|---|
| ndc | 52544-691-19 |
| ndc | 52544-691-10 |
| ndc | 52544-692-30 |
| ndc | 52544-692-19 |
| ndc | 52544-692-10 |
| ndc | 52544-693-30 |
| ndc | 52544-693-19 |
| ndc | 52544-693-10 |
| ndc | 52544-694-30 |
| ndc | 52544-694-19 |
| ndc | 52544-694-10 |
| ndc | 52544-695-30 |
| ndc | 52544-695-19 |
| ndc | 52544-695-10 |
| code_info | Lot 1411593A, Exp 09/22 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1302-2022%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.